化瘀软肝解毒方治疗乙型肝炎后肝硬化患者疗效观察  

Therapeutic Effect of Huayu Rugan Jiedu Prescription(化瘀软肝解毒方)on Patients with Post-Hepatitis B Cirrhosis

作　　者：杨广栋[1] 韩雪 赵宁宁 龚汶[1] 王庆海[1] 李文香[1] YANG Guangdong;HAN Xue;ZHAO Ningning;GONG Wen;WANG Qinghai;LI Wenxiang(Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine·Hebei,Cangzhou 061001,Hebei,China)

机构地区：[1]河北省沧州中西医结合医院,河北沧州061001

出　　处：《辽宁中医杂志》2024年第12期79-82,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局科研计划一般项目(2022251)。

摘　　要：目的探究化瘀软肝解毒方治疗乙型肝炎后肝硬化患者的疗效。方法随机选取2021年1月—2021年12月在该院接受治疗的乙型肝炎后肝硬化患者120例,采用随机数表法分为观察组(62例)和对照组(58例)。对照组采用富马酸替诺福韦酯治疗,观察组在对照组基础上联合化瘀软肝解毒方治疗。比较两组治疗疗效、不良反应发生率,同时检测治疗前后血清肝纤维化指标[透明质酸(hyaluronic acid,HA)、层黏连蛋白(laminin,LN)]、肝功能指标[谷丙转氨酶(alanine aminotransferase,ALT)、总胆红素(bilirubin,TBil)]、肾功能指标[内生肌酐清除率(endogenous creatinine clearance,Ccr)、β2-微球蛋白(β2-microglobulin,β2-MG)]以及基质金属蛋白酶组织抑制物-1(tissue inhibitor-1 of metalloproteinase,TIMP-1)表达水平。结果观察组治疗总有效率高于对照组(P<0.05),两组均未发生明显不良反应。治疗后,观察组血清HA、LN、TIMP-1、ALT以及TBil均低于对照组,差异具有统计学意义(P<0.05),两组肾功能指标Ccr、β2-MG差异无统计学意义(P>0.05)。结论联合使用化瘀软肝解毒方和富马酸替诺福韦酯治疗乙型肝炎后肝硬化具有更好的临床疗效,在改善患者肝功能和肝纤维化指标均具有优势,值得临床进一步验证及推广。Objective To explore the therapeutic effect of Huayu Rugan Jiedu Prescription(化瘀软肝解毒方)on patients with post-hepatitis B cirrhosis.Methods Between January 2021 to December 2021,a total of 120 patients with who received treatment in the hospital were randomly selected and divided into observation group(62 cases)and control group(58 cases)by random number table method.The control group was treated with tenofovir,and the observation group was treated with Huayu Rugan Jiedu Prescription on the basis of the control group.The therapeutic efficacy and incidence of adverse reactions were compared between the two groups.At the same time,the expression levels of serum hepatic fibrosis indexes[hyaluronic acid(HA),laminin(LN)],liver function indexes[alanine aminotransferase(ALT),bilirubin(TBil)],renal function indexes[endogenous creatinine clearance(Ccr),β2-microglobulin(β2-MG)]and tissue inhibitor-1 of metalloproteinase(TIMP-1)before and after treatment were detected.Results The total effective rate of the observation group was higher than that of the control group(P<0.05),and both groups did not experience adverse reactions.After treatment,the levels of serum LN,HA,TIMP-1,ALT and TBil in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05),while the renal function indexes Ccr andβ2-MG were not statistically significant between the two groups(P>0.05).After treatment,the main diameter of portal vein and the width of splenic vein in the observation group were smaller than those in the control group.Conclusion The combined use of Huayu Rugan Jiedu Prescription and entecavir has better clinical efficacy in the treatment of post-hepatitis B cirrhosis.The treatment has advantages in improving the liver function and liver fibrosis indicators,and further verification and promotion are worthy of clinical exploration.

关 键 词：乙型肝炎后肝硬化 化瘀软肝解毒方 肝功能 肾功能 安全性 

分 类 号：R256.4[医药卫生—中医内科学]